Evidence map›Paper›PMID 30798587›Full record

ArticleClinical and molecular hepatology2019

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.

Shinya Sato, Kei Moriya, Masanori Furukawa, Soichiro Saikawa, Tadashi Namisaki, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Naotaka Shimozato and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and molecular hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Hemolytic anemia in COVID-19.Annals of hematology · 2022
    Review
  5. Can l-carnitine reduce post-COVID-19 fatigue?Annals of medicine and surgery (2012) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Shinya SatoDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Kei MoriyaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Masanori FurukawaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Soichiro SaikawaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Tadashi NamisakiDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Mitsuteru KitadeDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Hideto KawarataniDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Kosuke KajiDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Hiroaki TakayaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Naotaka ShimozatoDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Yasuhiko SawadaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Kenichiro SekiDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Koh KitagawaDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Takemi AkahaneDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Akira MitoroDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Yasushi OkuraDepartment of Endoscopy, Nara Medical University, Nara, Japan.
Junichi YamaoDepartment of Endoscopy, Nara Medical University, Nara, Japan.
Hitoshi YoshijiDivision of Gastroenterology and Hepatology, Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimsL-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively evaluated the preventative efficacy of L-carnitine supplementation against hemolytic anemia during antiviral treatment using ribavirin in patients with hepatitis C virus (HCV)-related chronic liver disease.

methodsA total of 41 patients with chronic hepatitis were consecutively enrolled in this study. Group A (n=22) received sofosbuvir plus ribavirin for 3 months, whereas group B (n=19) was treated with sofosbuvir, ribavirin, and L-carnitine. Hemoglobin concentration changes, the effects of antiviral treatment, and the health status of patients were analyzed using short form-8 questionnaires.

resultsA significantly smaller decrease in hemoglobin concentration was observed in group B compared to group A at every time point. Moreover, the prescribed dose intensity of ribavirin in group B was higher than that of group A, resulting in a higher ratio of sustained virological response (SVR) 24 in group B compared with group A. The physical function of patients in group B was also significantly improved compared to group A at the end of antiviral treatment.

conclusionL-carnitine supplementation alleviates ribavirin-induced hemolytic anemia in patients with HCV and helps relieve the physical burden of treatment with ribavirin-containing regimens. These advantages significantly increase the likelihood of achieving SVR.

Indexed as

AgedAnemia, HemolyticCarnitineDrug Therapy, CombinationFemaleHepatitis CHumansMaleMiddle AgedQuality of LifeRibavirinSofosbuvirSurveys and QuestionnairesTreatment OutcomeCarnitineRibavirinSofosbuvirChronic hepatitis CDrug therapyHemolytic anemiaL-carnitineRibavirin

Identifiers

PMID30798587
PMCPMC6435976
OpenAlexW2916201893

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.